LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by OvaScience between February 25, 2013 and September 10, 2013, concerning the Company’s business and operations.
Please contact us at (646) 539-8980, or at firstname.lastname@example.org to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
OvaScience is engaged in the discovery, development and commercialization of new treatments for infertility. The Company’s first fertility treatment is AUGMENT – an assisted reproductive technology which complements the existing standard of practice for an in vitro fertilization cycle. The investigation is related to allegations that the Company misrepresented or failed to disclose material information concerning the clinical development of AUGMENT and regulatory concerns raised by the Food and Drug Administration that could potentially threaten or delay FDA approval of AUGMENT.
On September 10, 2013, OvaScience disclosed that it was suspending enrollment of the AUGMENT clinical trial in the United States, after the Company received a letter from the FDA questioning whether AUGMENT qualified for reduced regulatory oversight and advising the Company to file an Investigational New Drug application. Following this news, OvaScience shares dropped more than 23%, or $3.32 per share, to close at $10.95 per share on September 11, 2013.
If you purchased OvaScience securities between February 25, 2013 and September 10, 2013, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 122 East 42nd Street, Suite 2920, New York, NY 10168, at (646) 539-8980, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.